Bibliography
- CHIKANZA IC, SAKKAS LI: Advances in the therapy of rheumatoid arthritis. Emerging Drugs (2000) 5: 367–384.
- GNIADECKI R, CALVERLY MJ: Emerging drugs in psoriasis. Expert Opin. Emerging Drugs (2002) 7:69–90.
- ••A carefully organised and detailed review ofnew treatments in psoriasis from agents currently in the discovery phase to those in later development trials.
- KRENSKY AM, STROM TB, BLUESTONE JA: Immunomodulators: immunosuppressive agents, tolerogens, and immunostimulants. In: Goodman and Gilman's The pharmacological bash of therapeutics. Hardman JG, Limbird LE (Eds), McGraw Hill, New York (2001):1463–1484.
- •A thorough, concise introduction to the clinical pharmacology of irnmunomodulators for those new to the field or those wishing to renew their basic knowledge.
- KARIM M, BUSHELL AR, WOOD KJ: Regulatory T cells in transplantation. Carr: Opin. Immunol (2002) 14:584–591.
- KREUWAL HTC, SHERMAN LA: The T cell repertoire available for recognition of self-antigens. Can: Opin. Immunol (2001) 13:639–643.
- VAN DEN BERGHE L: Introduction to transplant immunology and immunosuppression. Mosby International, Inc, London (1999).
- BERNARD A, LAMY L, ALBERTI IM: The two-signal model of T-cell activation after 30 years. Transplantation (2002) 73:S31–S35.
- ••A very detailed update on one of the mostbasic elements of immunology — T cell signalling. Contains thoughtfully organised and illustrated information.
- HONG JC, KAHAN BD: Immunosuppressive agents in organ transplantation: past, present, and future. Semin. Nephrol (2000) 20:108–125.
- CIANCIO G, BURKE GW, MILLER J: Current treatment practice in immunosuppression. Expert Opin. Pharmacother. (2000) 1:1307–1330.
- TARANTINO A, MONTAGNINO G, PONTICELLI C: Corticosteroids in kidney transplant recipients: safety issues and timing of discontinuation. Drug Safety (1995) 13:145–156.
- PASCUAL M, THERUVATH T, KAWAI T,TOLKOFF-RUBIN N, COSIMI B: Strategies to improve long-term outcomes after renal transplantation. N Engl. I Med. (2002) 346:580–590.
- DAVIDSON A, DIAMOND B: Autoimmune diseases. N Engl. I Med. (2001) 345:340–350.
- •A concise review of the classification, pathology, and therapeutic strategies for autoimmune diseases.
- SARAVANAN V, HAMILTON J: Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opin. Pharmacother. (2002) 3:845–856.
- ••This review provides a clinical update onnew agents and treatment paradigms in rheumatology. It adopts a perspective from a practitioner's viewpoint on the emerging place of new therapies vis-à-vis the traditional disease-modifying agents.
- TAYLOR PC, WILLIAMS RO, MAINI RN: Immunotherapy for rheumatoid arthritis. Curt: Opin. Immunol (2001) 13:611–616.
- •A concise and useful summary of current information on immunotherapy in rheumatoid arthritis, with a helpful bibliography for those seeking quick access to the most pertinent recent literature on this subject.
- AMERICAN COLLEGE OF RHEUMATOLOGY SUBCOMMITTEE ON RHEUMATOID ARTHRITIS: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritic Rheum. (2002) 46:328–346.
- GABAY C: Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin. Biol. The]: (2002) 2:135–149.
- NO AUTHORS LISTED: Guidelines for management of patients with psoriasis. Br.jMed. (1991) 303:829–835.
- GOODIN DS: Therapeutic developments in multiple sclerosis. Expert Opin. Investig. Drugs (2000) 9:655–670.
- ••A critical presentation of current andemerging irnmunotherapies in multiple sclerosis, covering trial design considerations, outcomes measures, and the place of new therapies in the treatment of various disease stages or forms from the perspective of the practising neurologist.
- CLEGG A, BRYANT J: Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin. Pharmacother. (2001) 2:623–639.
- ••A critical review of new immunomodulators for the treatment of multiple sclerosis as viewed through the lens of clinical and cost effectiveness, compared with older treatment regimens. Provides a complementary perspective to the solely scientific one.
- RUIZ-IRASTORZA G, KHAMASHTA MA, HUGHES GRV: Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin. Invest. Drugs (2000) 9:1581–1593.
- •Presents the best evidence published between 1996 and 2000 on current treatment of lupus and gives an overview of novel approaches being tested clinically.
- HALLORAN PF: Call for revolution: a new approach to describing allograft deterioration. Am. I Transplant. (2002) 2:195–200.
- ••A seminal paper challenging transplantersto take a more circumspect view of chronic allograft deterioration, recognising the interplay between multifactorial stresses and the organ's ability to respond to them.
- VAZQUEZ MA: Chronic rejection of renal transplants: new clinical insights. Am. J. Med. Sci. (2000) 320:43–58.
- STEINMAN L: Immunotherapy of multiple sclerosis: the end of the beginning. Curr. Opin. Immunol (2001) 13:597–600.
- ••A far-ranging look at the immunotherapyof multiple sclerosis from currently available treatments through ongoing clinical trials with new agents and a look ahead to upcoming approaches in the research and discovery pipeline.
- KISHIMOTO K, DONG VM, SAYEGH MH: The role of costimulatory molecules as targets for new immunosuppressives in transplantation. Curr. Opin. Um]. (2000) 10:57–62.
- DUMONT FJ: Immunosuppressive strategies for prevention of transplant rejection. Expert Opin. Ther. Patents (2001) 11:377–404.
- BEHREND M: Immune-adhesion molecules in the prevention of allograft rejection and reperfusion injury. Expert Opin. Invest. Drugs (2000) 9:789–805.
- NASHAN B: Review of the proliferation inhibitor everolimus. Expert Opin. Invest. Drugs (2002) 11:1845–1857.
- SALVADORI M: Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients. Transplant. Proc. (2001) 33:3245–3247.
- ABEL MD, ASPESLET LJ, BROSKI AP et al.: Phase II trial results of I5Atx247, a novel calcineurin inhibitor, in renal transplantation (Abstract). Am. Transplant. (2002) 2\(Suppl. 3):379.
- DUMONT FJ: Alemtuzumab. Curr. Opin. Invest. Drugs (2001) 2:139–160.
- KREUGER GG: Selective targeting of T cell subsets: focus on alefacept-a remittive therapy for psoriasis. Expert Opin. Biol. Ther. (2002) 2:431–441.
- MORELAND LW, ALTEN R, VAN DEN BOSCH F et al.: Costimulatory blockade in patients with rheumatoid arthritis. Arthritic Rheum. (2002) 46:1470–1479.
- NAJAFIAN N, SAYEGH MH: CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Invest. Drugs (2000) 9:2147–2157.
- DEDRICK RL, WALICKE P, GAROVOY M: Anti-adhesion antibodies: efalizumab, a humanized anti-CD1la monoclonal antibody. Transplant. Immunol (2002) 9:181–186.
- DUMONT FJ: FTY-720.Carr: Opin. Andinflam. Immunomod. Invest. Drug (2000) 2:314–331.
- SKERJANEC A, HSU CH, PELLET P et al.: Systemic exposure and preliminary efficacy of FTY720 in de novo renal transplant recipients (abstract). Am. J. Transplant. (2002) 2\(Suppl. 3):380.
- BRINKMANN V, LYNCH KR: FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curt: Opin. Immunol (2002) 14:569–575.
- GLENNIE MJ, JOHNSON PWM: Clinical trials of antibody therapy. Immunol Today (2000) 21:403–410.
- ADAIR F: Monoclonal antibodies: magic bullets or a shot in the dark? Drug Discov. World (2002) 3:53–59.
- LAMONT AG: Novel and selective immunomodulatory drugs. Emerging Drugs (2000) 5:299–308.
- HUNSICKER LC, BENNETT LE: Design of trials of methods to reduce late renal allograft loss: the price of success. Kidney Int. (1995) 48\(Suppl. 52):5120–5123.
- BIOMARKERS DEFINITION WORKING GROUP: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol Ther. (2001) 69:89–95.
- FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritic Rheum. (1995) 38:727–735.
- FREDERIKSSON T, PETTERSSON U: Severe psoriasis-oral therapy with a new retinoid. Dermatologica (1978) 157:238–244.
- AMATO MP, PONZIANI G, BARTELEZZI ML, SIRACUSA G: A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. Neurol Sci. (1999) 168:96–106.
- RUDICK RA, ANTEL J, CONFAVREAUX C et al.: Recommendations from the National Multiple Sclerosis Society clinical outcomes assessment task force. Ann. Neurol (1997) 42:379–382.
- CUTTER GR, BAIER MS, RUDICK RA et al.: Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 122:101–112.
- GOODIN DS: The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology(1991) 41: 980–985.
- KAHAN BD: Synergism, how assessed andhow achieved. Clin. Transplant. (1991) 5:534–539.
- FOOD AND DRUG ADMINISTRATION: Draft guidance for industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis. (1997).
- ••Although this remains a draft guidance, itserves as an excellent example of how regulatory guidances dealing with alternative labelling claims and study design options could be organised to guide drug developers.
- SALAMA AD, SAYEGH MH: Challenges for the translation of T cell costimulatory blockade therapies to the clinic. Expert Opin. Biol. Ther. (2002) 2:453–457.
- •A brief overview of difficulties encountered in bringing costirnulatory antagonists to transplant medicine from researchers active in this field. Contains a helpful bibliography for readers who wish to delve more deeply into the details.
- MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. J. Med. (2003) 348:15–28.
Website
- http://www.unos.org United Network for Organ Sharing.
- http://www.whocc.no/atcddd/news/ 83 html World Health Organization Centre for Drug Statistics Methodology.
- http://www.iddb3.com Investigational Drugs Database, Current Drugs Limited.